dlvr.it
Senolytics dasatinib and quercetin in metabolic dysfunction-associated steatohepatitis: a proof-of-principle randomized, controlled trial
Nature Metabolism, Published online: 01 October 2026; doi:10.1038/s42255-026-01643-4In a double-blind, placebo-controlled trial, intermittent dasatinib and quercetin treatment over 21 weeks improves liver fibrosis in patients with MASH, as shown by paired liver biopsies, and reduces senescence and fibrotic gene signatures, as demonstrated by single-nucleus transcriptomics.